Table of Contents
Mutual Fund Calculator
What is Mutual Fund?
A mutual fund is a professionally managed investment scheme. It is run by an asset management company (AMC) which acts like a mediator for the retail investors. The AMC pools in money from a large number of investors and invests it in equity shares, Bonds, money market instruments and other types of securities. Buying a mutual fund is like buying a small slice of a big pizza. Each investor, in return, is assigned a specific number of units proportionate to his invested amount in the fund. The investor is known as the unit holder. The unit holder shares the gains, losses, income and expenses of the fund in proportion to his investment in the fund.
What is a Mutual Fund Calculator ?
Mutual Fund Calculator helps us in Calculating our interest return for SIP investments or lump sum investment with the help of Fincash Mutual Fund Calculator below.
How does a mutual fund calculator work?
Is your mutual fund scheme generating returns in line with your expectation? Are you wondering what amount of SIP would help you in personal goal accomplishment? Get your answers by using our Mutual Fund Calculator! The Mutual Fund Calculator will give you the investment value at maturity by calculating fund returns according to your investment horizon. You can adjust the variables of the calculator like SIP/lump sum, amount of investment, frequency of SIP, expected rate of return and duration of SIP
Nature of investment ( SIP / Lumpsum )
There are basically two ways of Investing money in your favourite Mutual Funds. You can go via the SIP or the lump sum route
1. Lump sum investment
Under a lump sum, you invest one big chunk of your funds in mutual fund scheme of your choice. It generally happens when you receive huge corpus from say sale of an asset or retirement benefits. But investing a lump sum involves greater risk. That’s why it is always recommended to go via the SIP route
2. Systematic Investment Plan (SIP)
Under a SIP, you instruct the bank to deduct a? the fixed sum from your Savings Account every month and invest it in the said mutual fund scheme. In this way, you can buy units continuously without worrying about the right time to enter the market. You get the benefit of rupee cost averaging and enjoy the Power of Compounding
Talk to our investment specialist
Types of Calculators
Lumpsum Calculator
SIP Calculator
Know Your SIP Returns
Top Funds for 2020
*Best funds based on 1 year performance.
"The primary investment objective of the Scheme is to seek capital appreciation by investing predominantly in units of MLIIF - WGF. The Scheme may, at the discretion of the Investment Manager, also invest in the units of other similar overseas mutual fund schemes, which may constitute a significant part of its corpus. The Scheme may also invest a certain portion of its corpus in money market securities and/or units of money market/liquid schemes of DSP Merrill Lynch Mutual Fund, in order to meet liquidity requirements from time to time. However, there is no assurance that the investment objective of the Scheme will be realized." DSP BlackRock World Gold Fund is a Equity - Global fund was launched on 14 Sep 07. It is a fund with High risk and has given a Below is the key information for DSP BlackRock World Gold Fund Returns up to 1 year are on (Erstwhile SBI Pharma Fund) To provide the investors maximum growth opportunity through equity
investments in stocks of growth oriented sectors of the economy. SBI Healthcare Opportunities Fund is a Equity - Sectoral fund was launched on 31 Dec 04. It is a fund with High risk and has given a Below is the key information for SBI Healthcare Opportunities Fund Returns up to 1 year are on The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies. Nippon India Pharma Fund is a Equity - Sectoral fund was launched on 5 Jun 04. It is a fund with High risk and has given a Below is the key information for Nippon India Pharma Fund Returns up to 1 year are on 1. DSP BlackRock World Gold Fund
CAGR/Annualized return of 5.9% since its launch. Ranked 11 in Global category. Return for 2019 was 35.1% , 2018 was -10.7% and 2017 was -4% . DSP BlackRock World Gold Fund
Growth Launch Date 14 Sep 07 NAV (09 Jul 20) ₹20.9183 ↑ 0.26 (1.28 %) Net Assets (Cr) ₹465 on 30 Apr 20 Category Equity - Global AMC DSP BlackRock Invmt Managers Pvt. Ltd. Rating ☆☆☆ Risk High Expense Ratio 1.67 Sharpe Ratio 1.19 Information Ratio -1.14 Alpha Ratio -9.76 Min Investment 1,000 Min SIP Investment 500 Exit Load 0-12 Months (1%),12 Months and above(NIL) Growth of 10,000 investment over the years.
Date Value 30 Jun 15 ₹10,000 30 Jun 16 ₹16,113 30 Jun 17 ₹12,630 30 Jun 18 ₹11,951 30 Jun 19 ₹13,529 30 Jun 20 ₹20,015 Returns for DSP BlackRock World Gold Fund
absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 9 Jul 20 Duration Returns 1 Month 17.6% 3 Month 39.1% 6 Month 46.6% 1 Year 64.2% 3 Year 21.4% 5 Year 18% 10 Year 15 Year Since launch 5.9% Historical performance (Yearly) on absolute basis
Year Returns 2019 35.1% 2018 -10.7% 2017 -4% 2016 52.7% 2015 -18.5% 2014 -3% 2013 -41.5% 2012 -5.8% 2011 -2.6% 2010 29% Fund Manager information for DSP BlackRock World Gold Fund
Name Since Tenure Jay Kothari 1 Mar 13 7.34 Yr. Data below for DSP BlackRock World Gold Fund as on 30 Apr 20
Equity Sector Allocation
Sector Value Basic Materials 93.62% Industrials 0.31% Asset Allocation
Asset Class Value Cash 4.13% Equity 94.85% Debt 0.02% Other 1% Top Securities Holdings / Portfolio
Name Holding Value Quantity BGF World Gold I2
Investment Fund | -97% ₹486 Cr 1,440,008
↑ 2,643 Treps / Reverse Repo Investments / Corporate Debt Repo
CBLO/Reverse Repo | -6% ₹29 Cr Net Receivables/Payables
Net Current Assets | -3% -₹14 Cr 2. SBI Healthcare Opportunities Fund
CAGR/Annualized return of 13% since its launch. Ranked 34 in Sectoral category. Return for 2019 was -0.5% , 2018 was -9.9% and 2017 was 2.1% . SBI Healthcare Opportunities Fund
Growth Launch Date 31 Dec 04 NAV (10 Jul 20) ₹147.679 ↑ 0.90 (0.61 %) Net Assets (Cr) ₹1,103 on 30 Apr 20 Category Equity - Sectoral AMC SBI Funds Management Private Limited Rating ☆☆ Risk High Expense Ratio 2.44 Sharpe Ratio 0.49 Information Ratio 0.08 Alpha Ratio 6.25 Min Investment 5,000 Min SIP Investment 500 Exit Load 0-15 Days (0.5%),15 Days and above(NIL) Growth of 10,000 investment over the years.
Date Value 30 Jun 15 ₹10,000 30 Jun 16 ₹9,715 30 Jun 17 ₹8,965 30 Jun 18 ₹8,175 30 Jun 19 ₹7,770 30 Jun 20 ₹10,369 Returns for SBI Healthcare Opportunities Fund
absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 9 Jul 20 Duration Returns 1 Month 0.6% 3 Month 10.2% 6 Month 22.7% 1 Year 36.8% 3 Year 4.9% 5 Year 0.5% 10 Year 15 Year Since launch 13% Historical performance (Yearly) on absolute basis
Year Returns 2019 -0.5% 2018 -9.9% 2017 2.1% 2016 -14% 2015 27.1% 2014 56.8% 2013 26% 2012 37.1% 2011 -5.5% 2010 29.1% Fund Manager information for SBI Healthcare Opportunities Fund
Name Since Tenure Tanmaya Desai 1 Jun 11 9.09 Yr. Data below for SBI Healthcare Opportunities Fund as on 30 Apr 20
Equity Sector Allocation
Sector Value Health Care 94.7% Industrials 1.8% Asset Allocation
Asset Class Value Cash 2.99% Equity 97.01% Top Securities Holdings / Portfolio
Name Holding Value Quantity Cipla Ltd (Healthcare)
Equity, Since 31 Aug 16 | 50008710% ₹117 Cr 1,800,000 Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Dec 17 | SUNPHARMA10% ₹114 Cr 2,400,000
↑ 300,000 Aurobindo Pharma Ltd (Healthcare)
Equity, Since 30 Apr 20 | AUROPHARMA8% ₹89 Cr 1,200,000
↑ 100,000 Lupin Ltd (Healthcare)
Equity, Since 31 Jul 18 | 5002578% ₹87 Cr 1,000,000 Divi's Laboratories Ltd (Healthcare)
Equity, Since 31 Mar 12 | DIVISLAB8% ₹86 Cr 360,000 Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 31 Mar 20 | 5001246% ₹71 Cr 175,000
↑ 50,000 Alembic Pharmaceuticals Ltd (Healthcare)
Equity, Since 31 Aug 17 | 5335735% ₹52 Cr 600,000
↓ -16,714 Abbott India Ltd (Healthcare)
Equity, Since 31 Mar 19 | 5004884% ₹50 Cr 30,000
↓ -2,000 Strides Pharma Science Ltd (Healthcare)
Equity, Since 31 Mar 14 | STAR3% ₹40 Cr 1,000,000 Biocon Ltd (Healthcare)
Equity, Since 31 Jan 20 | 5325233% ₹32 Cr 900,000 3. Nippon India Pharma Fund
CAGR/Annualized return of 20.1% since its launch. Ranked 35 in Sectoral category. Return for 2019 was 1.7% , 2018 was 3.6% and 2017 was 7.6% . Nippon India Pharma Fund
Growth Launch Date 5 Jun 04 NAV (10 Jul 20) ₹191.267 ↑ 1.11 (0.59 %) Net Assets (Cr) ₹2,851 on 30 Apr 20 Category Equity - Sectoral AMC Nippon Life Asset Management Ltd. Rating ☆☆ Risk High Expense Ratio 2.33 Sharpe Ratio 0.56 Information Ratio 1.68 Alpha Ratio 8.11 Min Investment 5,000 Min SIP Investment 100 Exit Load 0-1 Years (1%),1 Years and above(NIL) Growth of 10,000 investment over the years.
Date Value 30 Jun 15 ₹10,000 30 Jun 16 ₹10,010 30 Jun 17 ₹9,596 30 Jun 18 ₹10,671 30 Jun 19 ₹10,591 30 Jun 20 ₹14,086 Returns for Nippon India Pharma Fund
absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 9 Jul 20 Duration Returns 1 Month -0.9% 3 Month 11.7% 6 Month 25% 1 Year 36.4% 3 Year 12.9% 5 Year 7% 10 Year 15 Year Since launch 20.1% Historical performance (Yearly) on absolute basis
Year Returns 2019 1.7% 2018 3.6% 2017 7.6% 2016 -10.6% 2015 19.4% 2014 49.5% 2013 20.9% 2012 34.8% 2011 -11% 2010 31.9% Fund Manager information for Nippon India Pharma Fund
Name Since Tenure Sailesh Raj Bhan 1 Apr 05 15.26 Yr. Kinjal Desai 25 May 18 2.1 Yr. Data below for Nippon India Pharma Fund as on 30 Apr 20
Equity Sector Allocation
Sector Value Health Care 99.11% Asset Allocation
Asset Class Value Cash 0.89% Equity 99.11% Top Securities Holdings / Portfolio
Name Holding Value Quantity Aurobindo Pharma Ltd (Healthcare)
Equity, Since 31 Dec 15 | AUROPHARMA12% ₹358 Cr 4,800,000
↓ -200,000 Cipla Ltd (Healthcare)
Equity, Since 31 May 08 | 50008710% ₹311 Cr 4,800,000
↑ 1,000,000 Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 30 Jun 11 | 50012410% ₹303 Cr 745,000
↓ -5,000 Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Oct 09 | SUNPHARMA10% ₹299 Cr 6,300,976 Divi's Laboratories Ltd (Healthcare)
Equity, Since 31 Mar 12 | DIVISLAB9% ₹263 Cr 1,100,075 Lupin Ltd (Healthcare)
Equity, Since 31 Aug 08 | 5002578% ₹244 Cr 2,800,025
↑ 300,000 Syngene International Ltd (Healthcare)
Equity, Since 30 Nov 17 | 5392686% ₹171 Cr 4,798,751
↑ 498,751 Biocon Ltd (Healthcare)
Equity, Since 31 Aug 17 | 5325235% ₹142 Cr 4,007,778
↑ 500,000 Sanofi India Ltd (Healthcare)
Equity, Since 30 Jun 04 | 5006745% ₹135 Cr 175,000 Thyrocare Technologies Ltd (Healthcare)
Equity, Since 31 May 16 | THYROCARE4% ₹133 Cr 2,539,512
All efforts have been made to ensure the information provided here is accurate. However, no guarantees are made regarding correctness of data. Please verify with scheme information document before making any investment.
AMFI Registration No. 112358 | CIN: U74999MH2016PTC282153
Shepard Technologies Pvt. Ltd. (with ARN code 112358) makes no warranties or representations, express or implied, on products offered through the platform. It accepts no liability for any damages or losses, however caused, in connection with the use of, or on the reliance of its product or related services. Terms and conditions of the website are applicable.
©2020 Shepard Technologies Private Limited. All Rights Reserved